Paraytec develops high-performance detectors for the analytical and life sciences instrumentation market. The company has patented its innovative ActiPix™ technology for optical imaging and to measure the absorbance of fluid samples flowing in capillaries or fluid flow cuvettes. This technology allows researchers to measure the viscosity of drug formulations and the effective size of the active ingredients in these formulations.
Braveheart owns 50.77% of the issued share capital in Paraytec and also provides significant management resource to the company. As we own more than 50% of Paraytec we are deemed by the auditors to have control of the business and so consolidate the company accounts into Braveheart’s group accounts.
Find out more about Paraytec Limited